Pay in 4 interest-free payments of $6.51 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Read our full breakdown of the July 2026 review
December 5 Product: AstraZenecas Imfinzi Indication: Limited-stage small cell lung cancer AstraZeneca on Wednesday successfully expanded the label of its PD-L1 blocker Imfinzi (durvalumab), notching the FDAs greenlight for its use in patients with limited-stage small cell lung cancer who have not progressed after concurrent platinum chemotherapy and radiation therapy
It can donate reducing capacity, participate in enzyme reactions and then be regenerated through cellular recycling systems
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist
US$ 23.86
US$ 20.60
US$ 24.41
US$ 24.15
US$ 26.96
US$ 29.41
US$ 24.82
US$ 20.67
